Sanofi India share price today

Sanofi India Ltd's share price was ₹3,375.80 at the close on 5 November 2026. It has been falling for 64 weeks. That is 3.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,773 and ₹4,637, and at that close it sat 32% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sanofi India Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +25% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) cut their stake for 5 quarters in a row, best operating margin in 14 quarters and foreign funds (FIIs) raised their stake for 3 quarters in a row.

1. Indian funds and insurers (DIIs) cut their stake for 5 quarters in a row

   From 23.1% to 19.4% of the company by the September 2026 quarter.

2. Best operating margin in 14 quarters

   Operating margin was 33% in the September 2026 quarter, against 28% a year earlier.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 5.6% to 5.7% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Sanofi India reported revenue of ₹492 crore, up 3.6% from ₹475 crore a year earlier, and a profit of ₹117 crore, up 53.9% from ₹76.0 crore.

Sanofi India results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 5 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sanofi India closed at ₹3,375.80 on 5 November 2026, down 27.2% from ₹4,636.80 a year earlier (7 November 2025) and down 32.4% over five years. Its highest weekly close since March 2016 was ₹7,351.45 on 6 September 2024.

Sanofi India share price: then and now

Weekly closing prices. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 5 November 2026.

5 Nov 2026: ex-date for an interim dividend of ₹75 a share. 5 Nov 2026: Sanofi India closed at ₹3,375.80, up 5.4% on the week and up 14.6% on the month.

Earlier

• Results for July to September 2026: Revenue up 3.6% and profit up 53.9% on a year earlier.
• 5 Aug 2026: Sanofi India held its results call for April to June 2026. Management guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed.
• 22 Apr 2026: ex-date for a dividend of ₹48 a share.
• 7 Nov 2025: ex-date for an interim dividend of ₹75 a share.

Sanofi India paid ₹198 a share in regular dividends in the 12 months to 5 November 2026 (3 payments), a yield of 5.87% at the ₹3,375.80 close on 5 November 2026. The last was an interim dividend of ₹75 a share, ex-date 5 November 2026.

Sanofi India dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Sanofi India Ltd paid out 87% of its profit as dividends in FY25, and it paid a dividend in each of its last 12 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 5 August 2026, Sanofi India's management guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed.

“I am not expecting that we will reach industry growth in 2026. For 2027, this is what we are evaluating right now.”Rachid Ayari, on the call for April to June 2026

What management guided

• Partnership: industry growth not expected in 2026; recovery timing for 2027 remains under evaluation.
• Insulin market: high-single-digit growth expected over time, with analogs sustaining double-digit growth despite GLP-1.
• Exports: alternate-market offsets, Goa specialization and CMO insourcing to compensate mature-market losses.
• CSR: 600,000-plus direct beneficiaries to be reached by year-end through KiDS, Diabetes in Schools and mobile units.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 5 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Sanofi India reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Partnership growth: check whether OAD momentum broadens into CV and CNS after partner reorganization.

Sanofi India is on 2 of our India lists: Dividend stocks and Pharma stocks.

Sanofi India Ltd earned ₹117 Cr of net profit in the Sep 2026 quarter, +53.9% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was ₹327 Cr. Over 10 years profit has grown 0.2% a year on average. That is 23.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹76.0 Cr.

For the full year, FY25 profit was ₹327 Cr (−21.0% on the year before).

Why profit moved: revenue changed +3.6% on a year earlier and the margin moved +5.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +7.0% and revenue −4.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Sanofi India Ltd reported ₹492 Cr of revenue in the Sep 2026 quarter, +3.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown −1.8% a year on average. The last full year, FY25, came in at ₹1,837 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,822 Cr.

FY25 revenue was ₹1,837 Cr, −8.7% on the year before.

Recent pace: the last four quarters grew −4.7% on average, against −1.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −5.7%, against −3.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +2.5%, against −10.8% a year (accelerating).

Sanofi India Ltd's operating margin was 33.0% in the Sep 2026 quarter, 5.0 percentage points higher than the same quarter a year ago. Across 12 years it has been between 17.0% and 28.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.6 percentage points on the year while gross margin changed +2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 84% of Sanofi India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in ₹438 Cr of operating cash against ₹327 Cr of profit. After ₹23.0 Cr of spending on assets, ₹415 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 84% of profit came in as cash: the cash cycle got 50 days longer between FY20 and FY25, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Sanofi India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 83 days in FY25, up from 33 days in FY20. It spent ₹100 Cr on assets over the last 3 years. Customers take 35 days to pay, and stock sits for 127 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY25 sales of ₹1,837 Cr, each day of that cycle ties up about ₹5.0 Cr, so roughly ₹418 Cr is tied up in the business at any time.

FY25: customers took 35 days to pay and stock sat for 127 days, about 4.2 months of sales sitting as stock, for a full cycle of 83 days, longer than FY20's 33.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 127 days. Customers pay about 35 days after that. Suppliers are paid at 79 days. Together that makes the 83-day cycle.

Spending on assets: ₹100 Cr over the last 3 years, against ₹114 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹12.0 Cr (FY25): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Sanofi India Ltd's P/E is 21.3×, in the middle of its own history: higher than 44% of past readings. Its usual P/E (the middle reading) is 22.0×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.